Premium
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review
Author(s) -
Vaidya Shantashri,
Ghosh Kanjaksha,
Vundinti Babu Rao
Publication year - 2011
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2011.01689.x
Subject(s) - imatinib , medicine , myeloid leukemia , imatinib mesylate , drug resistance , drug , leukemia , pharmacology , oncology , biology , microbiology and biotechnology
A revolution in medical science was marked with the advent of imatinib, a site‐specific drug for the management of patients with chronic myeloid leukemia (CML). Imatinib mesylate (also known as Glivec, Gleevec, STI‐571, CGP57148), an orally administered 2‐phenylaminopyrimidine derivative approved by FDA in 2001 for the treatment for CML, is highly effective in treating the early stages of CML, but remission induced in advanced phase was observed to be relatively short‐lived. The primary cause of resistance in patients with CML is the mutations in the BCR–ABL kinase domain. This review discusses the different mechanisms leading to imatinib resistance and various treatment options to over‐ride imatinib resistance.